Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum.

Buono A, Lidbury JA, Wood C, Wilson-Robles H, Dangott LJ, Allenspach K, Suchodolski JS, Steiner JM.

Vet Immunol Immunopathol. 2019 Sep;215:109904. doi: 10.1016/j.vetimm.2019.109904. Epub 2019 Jul 27.

PMID:
31420068
2.

Treatment of feline injection-site sarcoma with surgery and iridium-192 brachytherapy: retrospective evaluation of 22 cats.

Bloch J, Rogers K, Walker M, Dawson J, Wilson-Robles H.

J Feline Med Surg. 2019 Apr 15:1098612X19844345. doi: 10.1177/1098612X19844345. [Epub ahead of print]

PMID:
30982391
3.

Long-term postoperative effects of administration of allogeneic blood products in 104 dogs with hemangiosarcoma.

Ciepluch BJ, Wilson-Robles HM, Pashmakova MB, Budke CM, Ellison GW, Thieman Mankin KM.

Vet Surg. 2018 Nov;47(8):1039-1045. doi: 10.1111/vsu.12967. Epub 2018 Sep 21.

PMID:
30242852
4.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.

Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30.

PMID:
30061364
5.

Removal of hemangiosarcoma cells from canine blood with a cell salvage system and leukocyte reduction filter.

Ciepluch B, Wilson-Robles H, Levine G, Smith R, Wright GA, Miller T, O'Brien MT, Thieman Mankin KM.

Vet Surg. 2018 Feb;47(2):293-301. doi: 10.1111/vsu.12760. Epub 2017 Dec 16.

PMID:
29247544
6.

Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol.

Wilson-Robles H, Budke CM, Miller T, Dervisis N, Novosad A, Wright Z, Thamm DH, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T.

Vet Comp Oncol. 2017 Dec;15(4):1564-1571. doi: 10.1111/vco.12302. Epub 2017 Apr 17.

PMID:
28419683
7.

In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.

Grayton JE, Miller T, Wilson-Robles H.

Vet Comp Oncol. 2017 Dec;15(4):1455-1467. doi: 10.1111/vco.12289. Epub 2017 Jan 30. No abstract available.

PMID:
28133930
8.

Oncology of Reptiles: Diseases, Diagnosis, and Treatment.

Christman J, Devau M, Wilson-Robles H, Hoppes S, Rech R, Russell KE, Heatley JJ.

Vet Clin North Am Exot Anim Pract. 2017 Jan;20(1):87-110. doi: 10.1016/j.cvex.2016.07.003. Review.

PMID:
27890294
9.

A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.

Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc AK.

PLoS One. 2016 Feb 11;11(2):e0149194. doi: 10.1371/journal.pone.0149194. eCollection 2016.

10.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.

PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.

11.

Assessing Combinational Drug Efficacy in Cancer Cells by Using Image-based Dynamic Response Analysis.

Sima C, Hua J, Cypert M, Miller T, Wilson-Robles HM, Trent JM, Dougherty ER, Bittner ML.

Cancer Inform. 2016 Mar 9;14(Suppl 5):33-43. doi: 10.4137/CIN.S30799. eCollection 2015.

12.

Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.

Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S.

J Immunother. 2014 Oct;37(8):407-15. doi: 10.1097/CJI.0000000000000052.

13.

Developing T cell cancer immunotherapy in the dog with lymphoma.

O'Connor CM, Wilson-Robles H.

ILAR J. 2014;55(1):169-81. doi: 10.1093/ilar/ilu020. Review.

PMID:
24936037
14.

Identification and evaluation of putative tumour-initiating cells in canine malignant melanoma cell lines.

Wilson-Robles HM, Daly M, Pfent C, Sheppard S.

Vet Comp Oncol. 2015 Mar;13(1):60-9. doi: 10.1111/vco.12019. Epub 2013 Feb 15.

PMID:
23410087
15.

Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.

Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, Safe S.

Mol Cancer Ther. 2012 Jan;11(1):108-18. doi: 10.1158/1535-7163.MCT-11-0548. Epub 2011 Oct 27.

Supplemental Content

Loading ...
Support Center